Centella pursuing radiotherapy-boosting drug for hypoxic tumors under new deal
This article was originally published in Scrip
Executive Summary
Centella Therapeutics gained the rights to an investigational drug from New Zealand-based Auckland UniServices designed to pump up the effectiveness of radiotherapy and chemotherapy used to treat oxygen-starved, or hypoxic, solid tumors.